Bibliography
- CONWAY JG, ANDREWS RC, BEAUDET B et al.: Inhibition of tumor necrosis factor-a (TNF-a) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-a-converting enzyme and matrix metalloproteinases. .1 Phannacol Exp. Mei: (2001) 298:900–908.
- MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. Ann. Intern. Med. (1999) 130:478–486.
- WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl. Med. (1999) 340:253–259.
- BANTHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl. Med. (2000) 343:1586–1593.
- MAINI R, ST CLAIR EW, BREED VELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. Lancet (1999) 354:1932–1939.
- LIPSKY PE, VAN DER HEIJDE DM, STCLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl. I Med. (2000) 343:1594–1602.
- BEUTLER BA: The role of tumor necrosis factor in health and disease. Rheurnatol (1999) 26(Suppl.e57):16–21.
- CONWAY JG, WAKEFIELD JA, BROWN HR et al.: Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by matrix metalloproteinase inhibitors. Exp. Med. (1995) 182:449–457.
- DIMARTINO M, WOLFF C, HIGH W et al.: Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF-a processing. Inflanon. Res. (1997) 46:211–215.
- LEWIS EJ, BISHOP J, BOTTOMLEY KMK et al: Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br. Pharinacol (1997) 121:540–546.
- BLACK RA, RAUCH CT, KOXLOSKY CJ et al.: A metalloproteinase disintegrin that releases tumour-necrosis factor-a from cells. Nature aondl (1997) 385:729–733.
- MOSS ML, JIN SL, MILLA ME et al: Cloning of a disintegrin metalloproteinase that processes precursor tumour necrosis factor-a. Nature (fond). (1997) 385:733–736.
- MCGEEHAN GM, BECHERER JD, BOYER CM et al.: Regulation of tumour necrosis factor-a by a metalloproteinase inhibitor. Nature aondl. 370:558–561.
- MOHLER KM, SLEATH PR, FITZNER JN et al.: Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature (fond). 370:218–220.
- CROWE PD, WALTER BN, MOHLER KM et al.: A metalloproteinase inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. Exp. Med. (1995) 181:1205–1210.
- MULLBERG J, DURIED FH, OTTEN-EVANS C et al.: A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor.' Inonunol. (1995) 155:5198–5205.
- LANZREIN M, GARRED 0, OLSNES S, SANDVIG K: Diptheria toxin endocytosis and membrane translocation are dependent on the intact membrane-anchored receptor (HB-EGF): studies on the cell-associated receptor cleaved by a metalloprotease in phorbol-ester-treated cells. Biochein..1. 310:285–289.
- SHAKO OR N, MICHALSKA M, HARRISCA, BLOCK JA: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 359:579–580.
- MOLLER DE: Potential role of TNF-a in the pathogenesis of insulin resistance and Type 2 diabetes. Trends Endocrinol Metab. (2000) 11:212–217.
- LEIB SL, CLEMENTS JM, LINDBERG RL et al.: Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain (2001) 124:1734–1742.
- RABINOWITZ MH, ANDREWS RC, BECHERER JD et al.: Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).Med. Chem. (2001) 44:4252–4267.
- XUE CB, VOSS ME, NELSON DJ et al.: Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. Med. Chem. (2001) 44:2636–2660.
- PARK JS, BAIK KU, CHO JY et al.: Noble 2- [3-(cyclopentyloxy)-4-methoxyphenyl] -1-isoindolinone derivatives. Part I: synthesis and SAR studies for the inhibition of TNF-alpha production. Arch. Pharm. Res. (2001) 24:367–370.